Top Stocks
Stock Comparison
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Ironwood Pharma Stock Analysis & Ratings
IRWD Stock Chart & Stats
Day’s Range$11.22 - $11.55
52-Week Range$10.13 - $14.27
Previous Close$11.46
Volume1.47M
Average Volume (3M)2.55M
Market Cap$1.75B
P/E Ratio3.6
Beta1.13
Next EarningsAug 04, 2022
EPS Forecast$0.34
Last Dividend Ex-DateApr 02, 2019
Dividend YieldN/A
1Y Price Target$14.50
Smart Score6
EPS (TTM)3.18
Ironwood Pharma News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $10.13 and its highest was $14.27 in the past 12 months.
What is Ironwood Pharma’s market cap?
Ironwood Pharma’s market cap is $1.75B.
What is Ironwood Pharma’s price target?
The average price target for Ironwood Pharma is $14.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $13.00. The average price target represents 27.30% Increase from the current price of $11.39.
The highest analyst price target is $16.00 ,the lowest forecast is $13.00. The average price target represents 27.30% Increase from the current price of $11.39.
What do analysts say about Ironwood Pharma?
Ironwood Pharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is Aug 04, 2022 which is in 75 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on May 05, 2022. The company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.315 by -$0.105.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.29 which represents an annual dividend yield of N/A. Ironwood Pharma’s last Notavailable dividend payment was on Apr 01, 2019. Ironwood Pharma’s upcoming ex-dividend date is Apr 02, 2019
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 153,840,000 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of $0.21 in its last earnings report, missing expectations of $0.315. Following the earnings report the stock price went down -1.29%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Among the largest hedge funds holding Ironwood Pharma’s share is HBK Investments LP. It holds Ironwood Pharma’s shares valued at 15M.
---
Ironwood Pharma Stock Analysis
Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Price Target
$14.50
Moderate Buy▲(27.30% Upside)
Analyst Forecast
Moderate Buy
Average Price Target: $14.50
Blogger Sentiment
Bullish
IRWD Sentiment 100% Sector Average 70%
Hedge Fund Holdings
▲ Increased
By 393.1K Shares Last Quarter.
Insider Transactions
N/A
Currently Not Enough Data Available
Retail Investors
Very Negative
Last 7 Days ▼ 1.3% Last 30 Days ▼ 2.3%
News Sentiment
N/A
Currently Not Enough Data Available
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.36%
12-Months-Change
Fundamentals
Return on Equity
167.94%
Trailing 12-Months
Asset Growth
80.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
---
---